Apologies, but no results were found. Perhaps searching will help find a related post.
Valuable contribution to understanding of kidney cancer treatment by patients participating in clinical trial. Outcomes of ECOG-ACRIN clinical trial for the treatment of locally advanced RCC in the adjuvant setting: Drugs used in metastatic kidney cancer do not prevent kidney cancer recurring after surgery Posted 5 March 2015: After surgery to remove cancer, additional ‘adjuvant’ treatments […]
Posted 29 February 2015: The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group will be holding the 2015 Annual Scientific Meeting (ASM) at Sofitel Wentworth Sydney from 12 -14 July. The ANZUP ASM brings together the multidisciplinary health professionals involved in researching and treating cancers of the genitourinary system. Highlights will include […]
Posted 7 January 2015: The Pharmaceutical Benefits Advisory Committee (PBAC) has approved both Sorafenib and Axitinib for treatment of stage IV (metastatic) clear cell variant renal cell carcinoma (RCC). These treatment options are for patients whose cancers have grown despite previous PBS-subsidised drug treatments (Sunitinib and Pazopanib). There are now five drugs available for Australians […]
Posted 1 December 2014: Kidney Health Australia provide resources and support for those affected by kidney cancer. Some of our established resources include a toll free phone and email information service, a dedicated website, an online community and a free Kidney Cancer Resource Pack which includes the Cancer Council’s Understanding Kidney Cancer booklet. Recently Kidney […]
Posted 24 November 2014: Results have been released from a phase II clinical trial testing the effectiveness of a combination of two existing anticancer drugs, bevacizumab and erlotinib, in treating advanced sporadic papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer (HLRCC). […]